Cleveland Heart

Cleveland Heart, Inc. has partnered with the Cleveland Clinic to develop the next generation of mechanical cardiac circulatory assist devices with the potential to provide a complete range of treatment options for patients suffering from irreversible end-stage heart failure.

Heart failure is a terminal disease affecting over 20 million patients worldwide. Approximately 1 million patients suffer from Class IV heart failure, the end stage of the disease. LVADs are used to bridge patients until a donor heart becomes available (Bridge-to-Transplant therapy) or, increasingly,
as a long-term alternative to transplantation
(Destination Therapy.)